Teva Reaches $420M Deal To End Investors' Price-Fixing Suit
By Dean Seal (January 18, 2022, 5:34 PM EST) -- Teva Pharmaceutical Industries Ltd. has agreed to pay $420 million to resolve an investor class action accusing the pharmaceutical giant of being at the center of an industrywide price-fixing scheme.
The $420 million, all-cash deal would be the second-largest securities class action settlement in the district, according to the class of investors. (AP Photo/George Widman)
The investor class asked a Connecticut federal judge on Tuesday to grant preliminary approval of an all-cash deal that would resolve securities claims against Teva, which is facing criminal charges over the alleged conspiracy to fix generic-drug prices.
If approved, the deal would be the Connecticut District's second-largest...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!